Total Funding
68
19
Total FundingPost-IPO Equity raised
Growth Score
-8 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4075678
Anadys Pharmaceuticals, a biopharmaceutical company, develops medicines for the treatment of hepatitis C.
About the Company
Anadys Pharmaceuticals is a biopharmaceutical company dedicated to developing medicines for the treatment of hepatitis C. The company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. Anadys has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts
via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.
